Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners (dental, medical, animal health) and institutions in North America and Europe. Operations are divided into two segments: Healthcare Distribution and Technology.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2007 |
Six Months Ended June 30, 2007 |
|---|---|---|
| Net Sales | $1,387,017 | $2,697,145 |
| Gross Profit | $413,777 | $804,823 |
| Gross Margin | 29.8% | 29.8% |
| Operating Income | $90,852 | $164,573 |
| Net Income (Continuing Ops) | $54,439 | $97,853 |
| Net Income (Total) | $33,837 | $77,331 |
| Diluted EPS (Total) | $0.37 | $0.86 |
| Cash from Operations (6mo) | $80,741 | |
| Total Debt | $480,457 | |
| Working Capital | $915,353 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16.3% ($194.0 million) for the quarter and 15.9% ($370.6 million) for the six months compared to the prior year. Growth was driven by organic volume increases and acquisitions, partially offset by foreign currency impacts.
- Discontinued Operations Impact: Total Net Income for the quarter decreased to $33.8 million from $45.2 million in the prior year, primarily due to a $32.7 million pre-tax impairment charge related to the decision to divest lower-margin oncology pharmaceutical and specialty pharmacy businesses. Excluding discontinued operations, income from continuing operations increased significantly.
- Segment Performance:
- Healthcare Distribution: Sales grew 15.9% (quarter) and 15.6% (six months). Gross margin remained stable at 28.8% for the six-month period.
- Technology: Sales grew 36.5% (quarter) and 30.6% (six months), driven by software and financial services. Gross margin decreased slightly to 74.0% (quarter) and 75.1% (six months) due to product mix changes.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 15.0% for the quarter but decreased as a percentage of sales to 23.3% from 23.5%.
- Cash Flow: Net cash provided by operating activities improved dramatically to $80.7 million for the six months ended June 30, 2007, compared to only $0.6 million in the prior year period, driven by improved working capital management.
Guidance, Outlook, and Risks
- Divestiture Plans: The company expects to sell the discontinued oncology and specialty pharmacy businesses within 12 months, anticipating an additional pre-tax loss of $3 million to $5 million upon sale.
- Acquisitions: Completed the acquisition of the remaining 50% of Becker-Parkin Dental Supply Co. for approximately $22 million. Announced an offer to acquire Software of Excellence International Ltd. for approximately $58 million.
- Capital Allocation: The company has $140.5 million remaining under its stock repurchase programs. It expects to invest $25 million to $30 million in capital projects for the remainder of the fiscal year.
- Tax Outlook: Management expects the effective tax rate to remain in the 34% to 35% range for the remainder of 2007.
- Risks: Key risks include industry consolidation, dependence on third-party suppliers, regulatory changes in healthcare, and foreign currency fluctuations. The company faces potential product liability claims, though management believes these are covered by insurance or indemnification.
Investor Verification Checklist
- Discontinued Operations: Verify the timeline and final financial impact of the divestiture of the oncology and specialty pharmacy businesses, including the anticipated $3-5 million additional loss.
- Acquisition Integration: Monitor the integration of Becker-Parkin and the progress of the proposed Software of Excellence acquisition.
- Working Capital Trends: Confirm the sustainability of the improved working capital metrics (DSO improved to 41.3 days; inventory turnover improved to 6.6 turns) that drove the surge in operating cash flow.
- Debt Structure: Review the terms of the $240 million convertible debt due in 2034 and the variable rate senior notes to assess interest rate exposure.
- Stock Repurchases: Track the utilization of the remaining $140.5 million repurchase authorization.